~~<i id='9532342874'><strike id='9532342874'><tt id='9532342874'><pre id='9532342874'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：explore 2025-09-30 20:14:54 Page View：94

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Maisha Meds is a PBM, but don't call it that
Next article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

explore

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Devoted Health’s losses in Medicare Advantage persist

CourtesyDevotedHealthDevotedHealthhasbeenoneofthemostprominenthealthinsuranceandproviderstartupsofth

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Why CTE doesn’t keep Americans from enjoying the Super Bowl

JoshuaA.Bickel/APInJanuary2023,minutesafterDamarHamlin collapsed onthefieldfollowingatackle,mycellph